Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
October 27 2022 - 4:05PM
Business Wire
- Dr. Stankovic to transition to advisory role
at year-end
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
its President, Srdjan (Serge) Stankovic, M.D., M.S.P.H., who is
responsible for R&D, and Medical and Scientific functions, will
retire at the end of the year. A search for a successor to Dr.
Stankovic is ongoing. Following his retirement, Dr. Stankovic will
provide consulting and advisory services for Acadia on a part-time
basis.
“I want to thank Serge for his seven years of dedicated service
to Acadia and the impact he’s had on the patients we serve that
will extend well beyond his tenure with us,” said Steve Davis,
Chief Executive Officer. “Serge played an instrumental role in
Acadia becoming a commercial stage company with the approval of
NUPLAZID® (pimavanserin) for Parkinson’s disease psychosis. Serge
led all of Acadia’s clinical and research efforts, including our
trofinetide new drug application currently under review for the
treatment of Rett syndrome by the FDA, and our ongoing Phase 3
program for pimavanserin for the treatment of the negative symptoms
of schizophrenia. Together with everyone at Acadia, I wish Serge
all the best in his retirement and very much look forward to
continuing to work with him in his new advisory role.”
“It has been an honor to serve as Acadia’s President and to be a
part of a dedicated team of professionals so committed to improving
the lives and wellbeing of patients in areas of high unmet medical
need,” said Dr. Stankovic, President. “As I look ahead to
retirement, I am proud to leave the company with a strong outlook
for the future, with an exceptional leadership team and a very
exciting R&D portfolio. I want to thank my Acadia colleagues,
the management team and the Board for their unwavering support and
encouragement during my tenure and I’d like to extend special
gratitude to our research participants who have been critical to
our success. I look forward to following the ongoing success and
growth of this great company.”
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our clinical-stage development
efforts are focused on treating the negative symptoms of
schizophrenia, Rett syndrome and neuropsychiatric symptoms in
central nervous system disorders. For more information, visit us at
www.acadia.com and follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221027006016/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024